Impact of the Pandemic on NonInfected Cardiometabolic Patients: A Survey in Countries of Latin America—Rationale and Design of the CorCOVID LATAM Study

LOPEZ SANTI, RICARDO; PISKORZ, DANIEL LEONARDO; MARQUEZ, MANLIO F.; RAMIREZ RAMOS, CRISTHIAN; RENNA, NICOLÁS FEDERICO; IBARROLA, MARTIN; WYSS, FERNANDO STUARDO; NARANJO DOMINGUEZ, ADRIÁN; PEREZ, GONZALO EMANUEL; FARINA, JUAN MARÍA; FORTE, EZEQUIEL; JUAREZ LLOCLLA, JORGE PAUL; FLORES DE ESPINAL, EMMA; PUENTE BARRAGAN, ADRIANA; RUISE, MAURO GABRIEL; DELGADO, DIEGO; BARANCHUK, ADRIAN

CJC Open

Elsevier Inc.

Año: 2020 vol. 2 p. 671 - 677

Background: The first case of coronavirus 2019 (COVID-19) in Latin America was detected on February 26th, 2020, in Brazil. Later, in June, the World Health Organization announced that the focus of the outbreak had shifted to Latin America, where countries already had poor control of indicators of noncommunicable diseases (NCDs). Concerns about coronavirus infection led to a reduced number of visits and hospitalizations in patients with NCDs, such as cardiovascular disease, diabetes, and cancer. There is a need to determine the impact of the COVID-19 pandemic on patients who have cardiometabolic diseases but do not have clinical evidence of COVID-19 infection. Methods: The CorCOVID LATAM is a cross-sectional survey of ambulatory cardiometabolic patients with no history or evidence of COVID-19 infection. The study will be conducted by the Interamerican Society of Cardiology. An online survey composed of 38 questions using Google Forms will be distributed to patients of 13 Latin American Spanish-speaking countries from June 15th to July 15th, 2020. Data will be analyzed by country and regions. Seven clusters of questions will be analyzed: demographics, socioeconomic and educational level, cardiometabolic profile, lifestyle and habits, body-weight perception, medical follow-up and treatments, and psychological symptoms. Results: Final results will be available upon completion of the study. Conclusions: The present study will provide answers regarding the impact of the COVID-19 pandemic on noninfected cardiometabolic patients. Data on this topic are scarce, as it is an unprecedented threat, without short-term solutions.